SYDNEY, AUSTRALIA--(Marketwired - June 19, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today advised that the Western Association of Gynecologic Oncologists (WAGO) Program Committee has accepted the abstract entitled "Treatment with Mucin 1-Autologous Dendritic Cell Therapy Significantly Improves Progression-Free Survival in Ovarian Cancer Patients in Second Remission" for oral presentation at the Ovarian Cancer Session at the 2014 WAGO Annual Meeting to be held from June 25-28, 2014 in California.
Dr. Heidi Gray, lead investigator, will deliver a presentation on final progression free survival (PFS) and interim overall survival (OS) data for Epithelial Ovarian Cancer patients in First or Second Remission (the CAN-003 protocol). As outlined in her presentation to the American Society of Clinical Oncology (ASCO) Annual Meeting on 31 May and as previously announced, Dr Gray will highlight the positive trends demonstrated in PFS and OS for CVac in the second remission patient population.
The following are specific details regarding Prima's presentation.
Event: 2014 WAGO Annual Meeting
Date: Thursday, June 26, 2014
Time: 10:35am - 10:45am
Location: Ritz Carlton Lake Tahoe, Salon III
About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au